Señales en vivo de ITCI | Maximiza tus Ganancias con Getagraph.com

COMPRAR 229 min ago

@ $69.20

Emitido: 1 jul 2024 @ 10:30

Retorno: -3.81%

Señal anterior: jul 1 - 09:48

Señal anterior: Vender

Retorno: -1.44 %

Live Chart Being Loaded With Signals

Commentary (1 jul 2024 @ 14:20):
Our systems believe the stock currently is overvalued by -0.06% compare to its pairs and should correct downwards.

Stats
Volumen de hoy	978 375
Volumen promedio	1.29M
Capitalización de mercado	7.03B
EPS	$-0.160 ( Q1 \| 2024-05-07 )
Próxima fecha de ganancias	( $-0.200 ) 2024-08-01
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-57.38 (Sector) 42.63 (Industry) 0
ATR14	$5.26 (7.90%)

ACOR -24.02%

ACRX 7.50%

ADMP 0.85%

ADMS 0.00%

AGRX 0.71%

AKAN -3.46%

ALIM -0.63%

AMPH -3.93%

AMYT 0.00%

ANIP -0.50%

AQST -6.35%

ASRT 0.40%

ATNX 0.00%

AVDL -1.00%

AYTU -4.12%

BFRI -2.00%

BGXX 6.67%

CLVR -1.89%

COLL 1.02%

CPIX -3.18%

CRDL -1.24%

CRON -1.71%

CYTH -3.40%

DCPH 0.00%

DERM -3.37%

DRRX 0.53%

DVAX -0.58%

EGRX -3.93%

EMBC -2.20%

EMBCV -9.33%

EOLS 1.66%

ESPR 5.39%

EVOK -4.54%

FLGC -3.19%

FLXN 0.00%

GHSI -1.68%

HCM 2.98%

HROW 1.53%

HUGE -7.95%

IMCC -3.78%

INCR 1.92%

IRWD 1.00%

ITCI -2.81%

IXHL 0.34%

JUPW 11.76%

KALA -0.47%

KIN 0.11%

KMDA -1.20%

LNTH -0.67%

NBIX 1.61%

NEPT 0.00%

NLTX 1.45%

OGI 0.32%

OPTN 2.40%

ORGO -1.25%

PAHC 2.15%

PCRX 0.49%

PETQ 1.72%

PLXP 0.00%

PPD 0.00%

PROC 3.48%

PRPH -3.35%

PTPI -3.40%

RDHL -0.65%

RDUS 1.18%

REPH -0.48%

RGC -5.03%

RMTI -2.27%

SCTL 0.92%

SCYX -5.00%

SIGA -0.72%

SISI -15.00%

SNDL 0.52%

SNOA 8.34%

SSIC -2.79%

SUPN -0.13%

SXTC 0.00%

THTX -1.41%

TKNO -10.22%

TLGT -13.85%

TLRY 1.20%

TXMD 5.90%

TYHT -3.90%

UPC 3.75%

VTRS -0.19%

ZYNE 2.36%

Insider Trading

Date	Person	Action	Amount	type
2024-06-23	Van Nostrand Robert L	Buy	1 567	Common Stock
2024-06-23	Van Nostrand Robert L	Sell	1 567	Restricted Stock Units
2024-06-23	Salas Eduardo Rene	Buy	1 567	Common Stock
2024-06-23	Salas Eduardo Rene	Sell	1 567	Restricted Stock Units
2024-06-23	Marcus Joel S	Buy	1 567	Common Stock

INSIDER POWER
6.03
Last 100 transactions
Buy: 523 231 \| Sell: 460 908

Correlación (AI algo v.1.1b): Overvalued: -0.06% $66.56 paired level. (El Algoritmo Rastrea Los Cambios De Las Acciones Más Correlacionadas En Tiempo Real Y Proporciona Una Actualización Instantánea)

Volumen Correlación

Largo: -0.89 (strong negative)

Corto: 0.80 (strong)

Signal:(51) Same movement expected

Intra-Cellular Therapies Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Intra-Cellular Therapies Correlación - Moneda/Commodity

0.55
( weak )

0.30
( neutral )

0.00
( neutral )

-0.06
( neutral )

-0.84
( strong negative )

-0.14
( neutral )

Intra-Cellular Therapies Finanzas

Annual	2023
Ingresos:	$462.18M
Beneficio Bruto:	$428.43M (92.70 %)
EPS:	$-1.460

FY	2023
Ingresos:	$462.18M
Beneficio Bruto:	$428.43M (92.70 %)
EPS:	$-1.460

FY	2022
Ingresos:	$249.13M
Beneficio Bruto:	$228.69M (91.79 %)
EPS:	$-2.72

FY	2021
Ingresos:	$83.80M
Beneficio Bruto:	$75.77M (90.41 %)
EPS:	$-3.50

Financial Reports:

No articles found.

Intra-Cellular Therapies Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Intra-Cellular Therapies

Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease and heart failure; ITI-1284-ODT-SL for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.